Investigational drugs for idiopathic pulmonary fibrosis

References

• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389:1941–1952..
   PubMed Web of Science ®Google Scholar
• Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest. 1996;110:1058–1067.
   PubMed Web of Science ®Google Scholar
• Raghu G, Anstrom KJ, King TE Jr, et al., Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–1977.
   PubMed Web of Science ®Google Scholar
• Myers JL, Katzenstein ALA. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest. 1988;94:1309–1311.
   PubMed Web of Science ®Google Scholar
• Kuhn C, Boldt J, King TE, et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989;140:1693–1703.
   PubMed Web of Science ®Google Scholar
• Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 2007;30:835–839.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Eng J Med. 2014;370:2071–2082..
   PubMed Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687.
   PubMed Web of Science ®Google Scholar
• Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. AJP Lung Cell Mol Physiol. 2010;298:L715–L731.
   Google Scholar
• Sheppard D. Integrin-mediated activation of transforming growth factor-beta(1) in pulmonary fibrosis. Chest. 2001;120:S49–S53.
   Web of Science ®Google Scholar
• Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997;100:768–776.
   PubMed Web of Science ®Google Scholar
• Saini G, Porte J, Weinreb PH, et al. αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur Respir J. 2015;46:486–494.
   PubMed Web of Science ®Google Scholar
• Lo DJ, Farris AB, Song M, et al. Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates. Am J Transpl. 2013;13:3085–3093.
   PubMed Web of Science ®Google Scholar
• van der Aar, E. M., Heckmann, B, Blanque, R, et al. Pharmacological profile and efficacy of GLPG1690, a novel autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;193:A4523.
   Web of Science ®Google Scholar
• Perrakis A, Moolenaar WH. Autotaxin: structure-function and signaling. J Lipid Res. 2014;55:1010–1018.
   PubMed Web of Science ®Google Scholar
• Umezu-Goto, M., Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002;158:227–233.
   PubMed Web of Science ®Google Scholar
• Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14:45–54.
   PubMed Web of Science ®Google Scholar
• Oikonomou N, Mouratis M-A, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;47:566–574.
   PubMed Web of Science ®Google Scholar
• van der Aar, E. M., Fagard L, Desrivot J, et al. Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;193:A2701.
   Web of Science ®Google Scholar
• Ongenaert M, Dupont S, Blanqué R, et al. Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF. Eur Respir J. 2016;48(Suppl. 60):OA4540.
   Google Scholar
• Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem. 2002;277:39436–39442.
   PubMed Web of Science ®Google Scholar
• Sonoda H, Aoki J, Hiramatsu T, et al. A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. J Biol Chem. 2002;277:34254–34263.
   PubMed Web of Science ®Google Scholar
• Chun J, Hla T, Lynch KR, et al. International union of basic and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010;62:579–587.
   PubMed Web of Science ®Google Scholar
• Llona-Minguez S, Ghassemian A, Helleday T. Lysophosphatidic acid receptor (LPAR) modulators: the current pharmacological toolbox. Prog Lipid Res. 2015;58:51–75.
   PubMed Web of Science ®Google Scholar
• Stoddard NC, Chun J. Promising pharmacological directions in the world of lysophosphatidic acid signaling. Biomol Ther (Seoul). 2015;23:1–11.
   PubMed Web of Science ®Google Scholar
• Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014;55:1192–1214.
   PubMed Web of Science ®Google Scholar
• Huang, L. S., Fu P, Patel P, et al. Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice. Am J Respir Cell Mol Biol. 2013;49:912–922.
   PubMed Web of Science ®Google Scholar
• Swaney J, Chapman C, Correa LD, et al. A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelb ph. Br J Pharmacol. 2010;160:1699–1713.
   PubMed Web of Science ®Google Scholar
• Leask A, Abraham DJ. TGF- signaling and the fibrotic response. Faseb J. 2004;18:816–827.
   PubMed Web of Science ®Google Scholar
• Pan LH, Yamauchi K, Uzuki M, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J. 2001;17:1220–1227.
   PubMed Web of Science ®Google Scholar
• Bonniaud P, Kolb M, Galt T, et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunol. 2004;173:2099–2108.
   PubMed Web of Science ®Google Scholar
• Allen JT, Knight RA, Bloor CA, et al. Enhanced insulin-like growth factor binding protein–related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 1999;21:693–700.
   PubMed Web of Science ®Google Scholar
• Raghu G, Scholand MB, De Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47:1481–1491.
   PubMed Web of Science ®Google Scholar
• Kubota S, Takigawa M. Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions. Clin Sci (Lond). 2015;128:181–196.
   PubMed Web of Science ®Google Scholar
• Leduc, M, Tremblay, M, Grouix, B, et al. PBI-4050, A novel first-in-class anti-fibrotic compound, inhibits CTgf and collagen I production in human alveolar epithelial cells and fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model. Am J Respir Crit Care Med. 2014;189:A1998.
   Web of Science ®Google Scholar
• Königshoff M, Rojas M. Galectin-3: the bridge over troubled waters. Am J Respir Crit Care Med. 2012;185:473–475.
   PubMed Web of Science ®Google Scholar
• Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185:537–546.
   PubMed Web of Science ®Google Scholar
• Hirani, N., Mackinnon, A, Nicol, L, et al. TD139, A novel inhaled galectin-3 inhibitor for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Results from the first in (IPF) patients study. QJM Int J Med. 2016;109:S16–S16.
   Google Scholar
• Kyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature. 1994;369:156–160.
   PubMed Web of Science ®Google Scholar
• Dérijard, B., Hibi M, Wu IH, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76:1025–1037.
   PubMed Web of Science ®Google Scholar
• Seimiya H, Mashima T, Toho M, et al. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem. 1997;272:4631–4636.
   PubMed Web of Science ®Google Scholar
• Wygrecka M, Zakrzewicz D, Taborski B, et al. TGF-β1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner. Am J Respir Cell Mol Biol. 2012;47:614–627.
   PubMed Web of Science ®Google Scholar
• Cui, Y., Osorio JC, Risquez C, et al. Transforming growth factor-β1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway. Mol Med. 2014;20:1.
   PubMed Web of Science ®Google Scholar
• Knight SD, Adams ND, Burgess JL, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett. 2010;1:39–43.
   PubMed Web of Science ®Google Scholar
• Wang M, Gao M, Miller KD, et al. [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers. Bioorganic Med Chem Lett. 2012;22:1569–1574.
   PubMed Web of Science ®Google Scholar
• Munster, P., Aggarwal R, Hong D, et al. First-in-human phase i study of GSK2126458, an oral pan-class i phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin Cancer Res. 2016;22:1932–1939.
   PubMed Web of Science ®Google Scholar
• Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov. 2010;9:956–970.
   PubMed Web of Science ®Google Scholar
• Kral JB, Kuttke M, Schrottmaier WC, et al. Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways. Sci Rep. 2016;6:23034.
   PubMed Web of Science ®Google Scholar
• Mercer PF, Woodcock HV, Eley JD, et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax. 2016;71:701–711.
   PubMed Web of Science ®Google Scholar
• Jin, X., Dai H, Ding K, et al. Rapamycin attenuates bleomycin-induced pulmonary fibrosis in rats and the expression of metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 in lung tissue. Chin Med J (Engl). 2014;127:1304–1309.
   PubMed Web of Science ®Google Scholar
• Xu X, Wan X, Geng J, et al. Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Exp Biol Med. 2013;238:1082–1094.
   Web of Science ®Google Scholar
• Xu X, Dai H, Geng J, et al. Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase. Lab Investig. 2015;95:846–859.
   PubMed Web of Science ®Google Scholar
• Lee JH, Zheng Y, Von Bornstadt D, et al. Selective ROCK2 inhibition in focal cerebral ischemia. Ann Clin Transl Neurol. 2014;1:2–14.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013;123:1096–1108.
   PubMed Web of Science ®Google Scholar
• Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev Pharmacol Rev. 2015;67:103–117.
   PubMed Web of Science ®Google Scholar
• Bei Y, Hua-Huy T, Duong-Quy S, et al. Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. Pulm Pharmacol Ther. 2013;26:635–643.
   PubMed Web of Science ®Google Scholar
• Jiang C, Huang H, Liu J, et al. Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. Int J Mol Sci. 2012;13:8293–8307.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Dobashi K, Iizuka K, et al. Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis. Am J Respir Crit Care Med. 2001;163:210–217.
   PubMed Web of Science ®Google Scholar
• Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014;111:16814–16819.
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658–6661.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias. N Engl J Med. 2006;354:2531–2541.
   PubMed Web of Science ®Google Scholar
• Montero JC, Seoane S, Ocaña A, et al. Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17:5546–5552.
   PubMed Web of Science ®Google Scholar
• Yilmaz O, Oztay F, Kayalar O. Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice. Growth Factors. 2015;33:366–375.
   PubMed Web of Science ®Google Scholar
• Germain RN, Stefanová I. The dynamics of T cell receptor signalin: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol. 1999;17:467–522.
   PubMed Web of Science ®Google Scholar
• Cruz FF, Horta LFB, Maia LDA, et al. Dasatinib reduces lung inflammation and fibrosis in acute experimental silicosis. PLoS One. 2016;11:1–17.
   Web of Science ®Google Scholar
• Schade, A. E., Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Cell. 2008;111:1366–1377.
   Google Scholar
• Chen C, Zhou J, Quercetin: JC. A potential drug to reverse multidrug resistance. Life Sci. 2010;87:333–338.
   PubMed Web of Science ®Google Scholar
• Murota K, Terao J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys. 2003;417:12–17.
   PubMed Web of Science ®Google Scholar
• Verma R, Kushwah L, Gohel D, et al. Evaluating the ameliorative potential of quercetin against the bleomycin-induced pulmonary fibrosis in wistar rats. Pulm Med. 2013;2013:1–10.
   Google Scholar
• Wei Q-F, Wang X-H, Zhang X-Y, et al. Therapeutic effects of quercetin on bleomycin induced pulmonary fibrosis in rats. Int J Clin Exp Med. 2016;9:5161–5167.
   Web of Science ®Google Scholar
• Murata T, Obiri NI, Puri RK. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med. 1998;1:551–557.
   PubMed Web of Science ®Google Scholar
• Wynn T. IL-13 effector functions. Annu Rev Immunol. 2003;21:425–456.
   PubMed Web of Science ®Google Scholar
• Park S-W-W, Ahn M-H, Jang HK, et al. Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. J Korean Med Sci. 2009;24:614–620.
   PubMed Web of Science ®Google Scholar
• Naik PK, Bozyk PD, Bentley JK, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012;303:L1046–56.
   PubMed Web of Science ®Google Scholar
• Corren, J., Hanania, R. F., Korenblat, N. A., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135:500–507.
   PubMed Web of Science ®Google Scholar
• Huaux F, Gharaee-Kermani M, Liu T, et al. Role of eotaxin-1 (CCL11) and CC Chemokine Receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am J Pathol. 2005;167:1485–1496.
   PubMed Web of Science ®Google Scholar
• Clarke DL, Murray LA, Crestani B, et al. Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis? Pharmacol Ther. 2017;169:35–46.
   PubMed Web of Science ®Google Scholar
• Maes T, Joos GF, Brusselle GG. Targeting Interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol. 2012;47:261–270.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–847.
   PubMed Web of Science ®Google Scholar
• Faffe DS, Whitehead T, Moore PE, et al. IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: role of IL-4 receptor genotype. Am J Physiol Lung Cell Mol Physiol. 2003;285:L907–L914.
   PubMed Web of Science ®Google Scholar
• Krensky AM, Clayberger C. HLA-derived peptides as novel immunosuppressives. Nephrol Dial Transplant. 1997;12:865–868.
   PubMed Web of Science ®Google Scholar
• Parra ER, Teodoro WR, Velosa APP, et al. Interstitial and vascular type V collagen morphologic disorganization in usual interstitial pneumonia. J Histochem Cytochem. 2006;54:1315–1325.
   PubMed Web of Science ®Google Scholar
• Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117:3498–3506.
   PubMed Web of Science ®Google Scholar
• Yasufuku K, Heidler KM, O’Donnell PW, et al. Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol. 2001;25:26–34.
   PubMed Web of Science ®Google Scholar
• Vittal R, Mickler EA, Fisher AJ, et al. Type V collagen induced tolerance suppresses collagen deposition, TGF-beta and associated transcripts in pulmonary fibrosis. PLoS One. 2013;8:e76451.
   PubMed Web of Science ®Google Scholar
• Wilkes DS, Chew T, Flaherty KR, et al. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1393–1402.
   PubMed Web of Science ®Google Scholar
• Lu J, Marjon KD, Mold C, et al. Pentraxins and Fc receptors. Immunol Rev. 2012;250:230–238.
   PubMed Web of Science ®Google Scholar
• Pilling D, Buckley CD, Salmon M, et al. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol. 2003;171:5537–5546.
   PubMed Web of Science ®Google Scholar
• Moreira AP, Cavassani KA, Hullinger R, et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore–induced allergic airway disease. J Allergy Clin Immunol. 2010;126:712–721.e7.
   PubMed Web of Science ®Google Scholar
• Murray, L. A., Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. 2010;5(3):e9683.
   Web of Science ®Google Scholar
• Dillingh MRR, Van Den Blink B, Moerland M, et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther. 2013;26:672–676.
   PubMed Web of Science ®Google Scholar
• Wilborn J, Bailie M, Coffey M, et al. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest. 1996;97:1827–1836.
   PubMed Web of Science ®Google Scholar
• Wardlaw, A. J.J, Hay H, Cromwell O, et al. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989;84:19–26.
   PubMed Web of Science ®Google Scholar
• Izumo T, Kondo M, Nagai A. Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis. Eur Respir J. 2009;34:1444–1451.
   PubMed Web of Science ®Google Scholar
• Miranda-Hernandez MP, López-Morales CA, Ramírez-Ibáñez ND, et al. Assessment of physicochemical properties of rituximab related to its immunomodulatory activity. J Immunol Res. 2015;2015:1–10.
   Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927–1932.
   Google Scholar
• Edwards JCW, Szczepański L, Szechiński J, et al. Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581.
   PubMed Web of Science ®Google Scholar
• Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19:353–359.
   PubMed Web of Science ®Google Scholar
• Leon RJ, Gonsalvo A, Salas R, et al. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc. 2004;79:949–953.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30:S17–S22.
   PubMed Web of Science ®Google Scholar
• Jordan, S., Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2014;74:1–7.
   Web of Science ®Google Scholar
• Xue J, Kass DJ, Bon J, et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol. 2013;191:2089–2095.
   PubMed Web of Science ®Google Scholar
• Donahoe, M., Valentine VG, Chien N, et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS One. 2015;10:1–17.
   Web of Science ®Google Scholar
• Ghadiri M, Young PM, Traini D. Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. Expert Opin Biol Ther. 2016;16:375–387.
   PubMed Web of Science ®Google Scholar
• Serrano-Mollar A, Nacher M, Gay-Jordi G, et al. Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2007;176:1261–1268.
   PubMed Web of Science ®Google Scholar
• Guillamat-Prats R, Gay-Jordi G, Xaubet A, et al. Alveolar Type II cell transplantation restores pulmonary surfactant protein levels in lung fibrosis. J Hear Lung Transplant. 2014;33:758–765.
   PubMed Web of Science ®Google Scholar
• Serrano-Mollar A, Gay-Jordi G, Guillamat-Prats R, et al. Safety and tolerability of alveolar type II cell transplantation in idiopathic pulmonary fibrosis. Chest. 2016;150:533–543.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Fujita T, Umezawa H, et al. Therapeutic effect of lung mixed culture-derived epithelial cells on lung fibrosis. Lab Invest. 2014;94:1247–1259.
   PubMed Web of Science ®Google Scholar
• Toonkel RL, Hare JM, Matthay MA, et al. Mesenchymal stem cells and idiopathic pulmonary fibrosis potential for clinical testing. Am J Respir Crit Care Med. 2013;188:133–140.
   PubMed Web of Science ®Google Scholar
• Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003;100:8407–8411.
   PubMed Web of Science ®Google Scholar
• Srour N, Thebaud B. Mesenchymal stromal cells in animal bleomycin pulmonary fibrosis models: a systematic review. Stem Cells Transl Med. 2015;4:1500–1510.
   PubMed Web of Science ®Google Scholar
• Yan, X., Liu Y, Han Q, et al. Injured microenvironment directly guides the differentiation of engrafted Flk-1+ mesenchymal stem cell in lung. Exp Hematol. 2007;35:1466–1475.
   PubMed Web of Science ®Google Scholar
• Glassberg, M. K., Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I, safety, clinical trial. Chest. 2016. DOI:10.1016/j.chest.2016.10.061
   PubMed Web of Science ®Google Scholar
• Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19:1013–1018.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med. 2013;11:171.
   PubMed Web of Science ®Google Scholar
• Lehtonen ST, Veijola A, Karvonen H, et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res. 2016;17:14.
   PubMed Web of Science ®Google Scholar
• Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1382–1392.
   PubMed Web of Science ®Google Scholar
• Longo DL, Rockey DC, Bell PD, et al. Fibrosis – a common pathway to organ injury and failure. N Engl J Med. 2015;372:1138–1149.
   PubMed Web of Science ®Google Scholar
• Cordier J-F-F, Cottin V. Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur Respir J. 2013;42:916–923.
   PubMed Web of Science ®Google Scholar
• Hecker L, Logsdon NJ, Kurundkar D, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med. 2014;6:231ra47–231ra47.
   PubMed Web of Science ®Google Scholar
• Antoniu SA, Kolb MR. Update on models of pulmonary fibrosis therapy for preclinical drug research. Expert Opin Drug Discov. 2009;4:939–946.
   PubMed Web of Science ®Google Scholar
• Königshoff M, Uhl F, Gosens R. From molecule to man: integrating molecular biology with whole organ physiology in studying respiratory disease. Pulm Pharmacol Ther. 2011;24:466–470.
   PubMed Web of Science ®Google Scholar
• Surolia, R, Li FJ, Wang Z, et al. 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI Insight. 2017;2(2):e91377.
   Web of Science ®Google Scholar